Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein detection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    139 result(s) found for: Protein detection. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2018-000215-24 Sponsor Protocol Number: GeSIDA10017 Start Date*: 2018-06-05
    Sponsor Name:Fundacion SEIMC-GESIDA
    Full Title: A single-arm, open-label and multicentre phase IV trial to evaluate the immunogenicity of the nonavalent vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017...
    Medical condition: AIDS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003142-27 Sponsor Protocol Number: RALAM Start Date*: 2015-07-13
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard com...
    Medical condition: Chronic HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004627-16 Sponsor Protocol Number: 70233 Start Date*: 2020-11-25
    Sponsor Name:Helsinki University Hospital
    Full Title: Clinical Validation of Quantitative Flutemetamol PET/CT in Cardiac Amyloidosis
    Medical condition: Cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000985-31 Sponsor Protocol Number: RALAM-II Start Date*: 2017-10-04
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: Phase 3b, single arm, single site simplification study with dual therapy including 3TC (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected atients experiencing inco...
    Medical condition: Virologically suppressed Human Immunodeficiency Virus-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020168 10020445 Human immunodeficiency virus type I infection with constitutional disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002751-19 Sponsor Protocol Number: 82160 Start Date*: 2023-04-11
    Sponsor Name:Amsterdam UMC
    Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients
    Medical condition: Inflammatory Bowel Diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000986-60 Sponsor Protocol Number: RALAM-Roll-Over Start Date*: 2017-10-11
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of 3TC (150 mg BID) plus Raltegravir (400 mg BID) switching to 3...
    Medical condition: Patients of RALAM study (NCT02284035)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020168 10020445 Human immunodeficiency virus type I infection with constitutional disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-006172-16 Sponsor Protocol Number: CoVVacBoost Start Date*: 2021-11-26
    Sponsor Name:Medical University of Graz
    Full Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study
    Medical condition: Covid (Coronavirus disease)- 19 immunisation
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000545-40 Sponsor Protocol Number: FELZ01 Start Date*: 2021-08-01
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial
    Medical condition: Late active or chronic active antibody-mediated rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001088-58 Sponsor Protocol Number: SELLY Start Date*: 2020-03-19
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: SEntinel Lymph node in EarLY ovarian cancer: the SELLY protocol
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001372-66 Sponsor Protocol Number: TACmono-100 Start Date*: 2014-07-16
    Sponsor Name:Erasmus Medical Center
    Full Title: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study.
    Medical condition: kidney transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005105-20 Sponsor Protocol Number: V48P4E3 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-de...
    Medical condition: Prophylaxis: Tick-borne-encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000675-13 Sponsor Protocol Number: PNS2014-01 Start Date*: 2016-02-03
    Sponsor Name:Erasmus University Medical Center
    Full Title: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Medical condition: Anti-Hu associated paraneoplastic neurological syndromes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021257-39 Sponsor Protocol Number: PB-PG-0808-16319 Start Date*: 2011-07-26
    Sponsor Name:SWBH NHS Trust [...]
    1. SWBH NHS Trust
    2. Keele University
    Full Title: Is it clinically effective to treat arm flexor spasticity, with Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle activity are observed? (A phase II study)
    Medical condition: Stroke.Spasticity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004634-41 Sponsor Protocol Number: IIBSP-FPI-2019-108 Start Date*: 2021-08-25
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome
    Medical condition: Taupathies
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002931-16 Sponsor Protocol Number: V501-122 Start Date*: 2018-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese men
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002790-35 Sponsor Protocol Number: C12-48 Start Date*: 2019-06-04
    Sponsor Name:INSERM
    Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector
    Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10074980 Epidermolysis bullosa aquisita LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000988-68 Sponsor Protocol Number: O2021-1 Start Date*: 2021-03-31
    Sponsor Name: Region Stockholm
    Full Title: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 .
    Medical condition: Renal failure stage 4 and 5.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 21:38:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA